Search
Echothiophate
go.drugbank.com/drugs/DB01057ApprovedInvestigationalA potent, long-acting irreversible cholinesterase inhibitor used as an ocular hypertensive in the treatment of glaucoma. Occasionally used for accomodative esotropia.
Synonyms: 2-(Diethoxyphosphorylsulfanyl)ethyl-N,N,N-trimethylazanium iodideProducts: Phospholine Iodide 3mg/5ml, Phospholine Iodide - Liq Pws 3mg/5mlPyruvic acid
go.drugbank.com/drugs/DB00119ApprovedInvestigationalNutraceuticalAn intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. … (From Stedman, 26th ed)
Remoxipride
go.drugbank.com/drugs/DB00409ApprovedWithdrawn[A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512] … Remoxipride is an atypical antipsychotic agent that is specific for dopamine D<sub>2</sub> receptors.
MB-102 CD123 CAR
go.drugbank.com/drugs/DB17366InvestigationalMB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.
Toripalimab
go.drugbank.com/drugs/DB15043ApprovedInvestigationalIt was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … The proliferation of some cancers can be attributed, at least in part, to the suppression of host tumor surveillance.
alpha-Arbutin
go.drugbank.com/drugs/DB14109ApprovedMixtures: Skin White Pro Strength Kojic and Hyaluronic Skin Lightening SerumIodamide
go.drugbank.com/drugs/DB08948ApprovedWithdrawnIodamide is a contrast medium molecule that is no longer marketed in the United States.
Categories: Compounds used in a research, industrial, or household settingProducts: UROMIRO 300 SODICOCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744] … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.
Lithium cation
go.drugbank.com/drugs/DB01356ApprovedInvestigationalWithdrawnThe active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several … They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression.